-
平臺(tái)編號(hào)：bio-69276
-
國(guó)際編號(hào)：TIB-196?
-
細(xì)胞信息： U266B1
-
規(guī)格：Frozen
-
用途：ATCC原裝細(xì)胞
-
服務(wù)費(fèi)用：
加載中…… - 訂購(gòu)
-
注意事項(xiàng)：僅用于科學(xué)研究或者工業(yè)應(yīng)用等非醫(yī)療目的不可用于人類或動(dòng)物的臨床診斷或治療，非藥用，非食用（產(chǎn)品信息以出庫(kù)為準(zhǔn)）
U266B1
運(yùn)輸方式：凍存運(yùn)輸
細(xì)胞形態(tài)：淋巴樣
免疫類型：IgE; lambda light chain
年限：53 years adult
ATCC Number：TIB-196?
相關(guān)疾?。浩渌膊?br /> 器官來(lái)源：外周血
細(xì)胞類型：B淋巴細(xì)胞
數(shù)量：大量
是否是腫瘤細(xì)胞：1
物種來(lái)源：人
生長(zhǎng)狀態(tài)：懸浮生長(zhǎng)
規(guī)格：100次 Designations: U266B1 [U266]
Depositors: ?NK Nilsson
Isotype: IgE; lambda light chain
Biosafety Level:1
Shipped: frozen
Medium & Serum: See Propagation Growth Properties:suspension
Organism: Homo sapiens
Morphology:lymphoblast
Source: Organ: peripheral blood
Disease: myeloma; plasmacytoma
Cell Type: B lymphocyte;
Cellular Products:immunoglobulin; monoclonal antibody; interleukin 6 (interleukin-6, IL-6)
Permits/Forms:In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.
Applications:transfection host
DNA Profile (STR):Amelogenin: X,Y
CSF1PO: 12,13
D13S317: 12
D16S539: 10
D5S818: 11,12
D7S820: 11,12
THO1: 5,7
TPOX: 8
vWA: 17
Age: 53 years adult
Gender: male
Comments:U266 cells have been reported to produce human IL-6.
Propagation: ATCC complete growth medium: The base medium for this cell line is ATCC-formulated RPMI-1640 Medium, Catalog No. 30-2001. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 15%.
Subculturing: Medium Renewal: Every 2 to 3 days
Cultures can be maintained by addition or replacement of fresh medium. Start cultures at 3 x 10 exp5 cells/ml and maintain between 1 x 10 exp5 and 1 x 10 exp6 cells/ml.
Preservation: culture medium 95%; DMSO, 5%
Related Products:Recommended medium (without the additional supplements or serum described under ATCC Medium):ATCC 30-2001
recommended serum:ATCC 30-2020
References: 1180: Nilsson K, et al. Established immunoglobulin producing myeloma (IgE) and lymphoblastoid (IgG) cell lines from an IgE myeloma patient. Clin. Exp. Immunol. 7: 477-489, 1970. PubMed: 4097745
22377: Kawano M, et al. Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas. Nature 332: 83-85, 1988. PubMed: 3258060
32396: Kolanus W, et al. alphaLbeta2 integrin/LFA-1 binding to ICAM-1 induced by cytohesin-1 a cytoplasmic regulatory molecule. Cell 86: 233-242, 1996. PubMed: 8706128
細(xì)胞形態(tài)：淋巴樣
免疫類型：IgE; lambda light chain
年限：53 years adult
ATCC Number：TIB-196?
相關(guān)疾?。浩渌膊?br /> 器官來(lái)源：外周血
細(xì)胞類型：B淋巴細(xì)胞
數(shù)量：大量
是否是腫瘤細(xì)胞：1
物種來(lái)源：人
生長(zhǎng)狀態(tài)：懸浮生長(zhǎng)
規(guī)格：100次 Designations: U266B1 [U266]
Depositors: ?NK Nilsson
Isotype: IgE; lambda light chain
Biosafety Level:1
Shipped: frozen
Medium & Serum: See Propagation Growth Properties:suspension
Organism: Homo sapiens
Morphology:lymphoblast
Source: Organ: peripheral blood
Disease: myeloma; plasmacytoma
Cell Type: B lymphocyte;
Cellular Products:immunoglobulin; monoclonal antibody; interleukin 6 (interleukin-6, IL-6)
Permits/Forms:In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.
Applications:transfection host
DNA Profile (STR):Amelogenin: X,Y
CSF1PO: 12,13
D13S317: 12
D16S539: 10
D5S818: 11,12
D7S820: 11,12
THO1: 5,7
TPOX: 8
vWA: 17
Age: 53 years adult
Gender: male
Comments:U266 cells have been reported to produce human IL-6.
Propagation: ATCC complete growth medium: The base medium for this cell line is ATCC-formulated RPMI-1640 Medium, Catalog No. 30-2001. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 15%.
Subculturing: Medium Renewal: Every 2 to 3 days
Cultures can be maintained by addition or replacement of fresh medium. Start cultures at 3 x 10 exp5 cells/ml and maintain between 1 x 10 exp5 and 1 x 10 exp6 cells/ml.
Preservation: culture medium 95%; DMSO, 5%
Related Products:Recommended medium (without the additional supplements or serum described under ATCC Medium):ATCC 30-2001
recommended serum:ATCC 30-2020
References: 1180: Nilsson K, et al. Established immunoglobulin producing myeloma (IgE) and lymphoblastoid (IgG) cell lines from an IgE myeloma patient. Clin. Exp. Immunol. 7: 477-489, 1970. PubMed: 4097745
22377: Kawano M, et al. Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas. Nature 332: 83-85, 1988. PubMed: 3258060
32396: Kolanus W, et al. alphaLbeta2 integrin/LFA-1 binding to ICAM-1 induced by cytohesin-1 a cytoplasmic regulatory molecule. Cell 86: 233-242, 1996. PubMed: 8706128
